RT Journal Article
SR Electronic
T1 <em>BRAF</em> and <em>K-RAS</em> Mutation in a Greek Papillary and Medullary Thyroid Carcinoma Cohort
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 305
OP 308
VO 28
IS 1A
A1 NIKOLAOS GOUTAS
A1 DIMITRIOS VLACHODIMITROPOULOS
A1 MYRTO BOUKA
A1 ANDREAS C. LAZARIS
A1 GEORGE NASIOULAS
A1 MARIA GAZOULI
YR 2008
UL http://ar.iiarjournals.org/content/28/1A/305.abstract
AB Background: The genes RAS and BRAF have been shown to be frequently mutated in human thyroid carcinomas. The aim of this study was to genotype a cohort of 55 sporadic papillary thyroid carcinomas (PTC) and 44 sporadic medullary thyroid carcinomas (MTC) for the K-RAS codon 12 and BRAF codon 600 mutations. Materials and Methods: K-RAS and BRAF mutations were characterized by an enhanced polymerase chain reaction followed by restriction fragment length polymorphism analysis (PCR-RFLP). Results: The K-RAS codon 12 mutation was found in 54.5% of the PTC and 40.9% of the MTC cases tested. The BRAF V600E mutation was detected in 27.3% of the PTC and 68.2% of the MTC samples. No significant association between K-RAS and BRAF mutations and clinicopathological parameters was found. Conclusion: These data indicate that K-RAS and BRAF mutations were a frequent genetic event in our samples of sporadic PTC and MTC.